

europaean journal of gynaecological oncology

an International Journal

Editors-in-Chief

A. Onnis **P. Bószé**
Montréal (Canada) *Budapest (Hungary)*

Associate Editor

M. Marchetti
Montréal (Canada)

Assistant Editor

J. Wilson
San Diego - CA (USA)

Editorial Board

Allen H.H., <i>London, Ontario (Canada)</i>	Friedrich M., <i>Luebeck (Germany)</i>	Marth C., <i>Innsbruck (Austria)</i>
Anteby S.O., <i>Jerusalem (Israel)</i>	Fuller A.F. Jr., <i>Boston, MA (USA)</i>	Massuger Leon F.A.G., <i>Nijmegen (The Netherlands)</i>
Audet-Lapointe P., <i>Montreal (Canada)</i>	Geisler H.E., <i>Indianapolis, IN (USA)</i>	Menczer J., <i>Savyon (Israel)</i>
Ayhan A., <i>Ankara (Turkey)</i>	Gerbaulet A., <i>Villejuif (France)</i>	Monsonogo J., <i>Paris (France)</i>
Balat O., <i>Graziantep (Turkey)</i>	Gorins A., <i>Paris (France)</i>	Pinotti A., <i>São Paulo (Brazil)</i>
Barber H.K., <i>New York, NY (USA)</i>	Heintz A.P.M., <i>Utrecht (The Netherlands)</i>	Piver S.M., <i>Buffalo, NY (USA)</i>
Basta A., <i>Krakow (Poland)</i>	Ioannidou-Mouzaka L., <i>Athens (Greece)</i>	Rakar S., <i>Ljubljana (Slovenia)</i>
Bender H.C., <i>Dusseldorf (Germany)</i>	Jordan J.A., <i>Birmingham, England (UK)</i>	Raju K.S., <i>London, England (UK)</i>
Benedetti Panici P.L., <i>Rome (Italy)</i>	Karseladze A.I., <i>Moscow (Russia)</i>	Shepherd J.H., <i>London, England (UK)</i>
Charkviani T., <i>Tbilisi (Georgia)</i>	Klastersky J., <i>Bruxelles (Belgium)</i>	Stelmachów J., <i>Warsaw (Poland)</i>
Dargent D., <i>Lyon (France)</i>	Kubista E., <i>Vienna (Austria)</i>	Ungár L., <i>Budapest (Hungary)</i>
De Oliveira C.F., <i>Coimbra (Portugal)</i>	Kudelka A.P., <i>Houston, TX (USA)</i>	Vermorken J.B., <i>Edegem (Belgium)</i>
Dexeus S. Jr., <i>Barcelona (Spain)</i>	Maggino T., <i>Padua (Italy)</i>	Vírtej P., <i>Bucharest (Romania)</i>
De Palo G., <i>Milan (Italy)</i>	Markowska J., <i>Poznan (Poland)</i>	Wang P.-H., <i>Taipei (Taiwan)</i>
Di Paola G.R., <i>Buenos Aires (Argentina)</i>		Winter R., <i>Graz (Austria)</i>
Di Re F., <i>Milan (Italy)</i>		Yokoyama Y., <i>Hirosaki (Japan)</i>
Di Saia P., <i>Orange, CA (USA)</i>		

Publishing Organization (M. Morsani):

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroun-online.com - www.irog.net

Editorial Office (M. Critelli):

Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

European Journal of Gynaecological Oncology

www.irog.net

General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted six months before publication and will be published free of charge.

BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.

COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H3, Tél. 514.4893242-4893640, Fax 514.4854513, E-mail: canlux@mggroup-online.com - www.irog.net

RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate information, the publisher accepts no responsibility for the consequences of faulty or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.

SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is \$390 US for Institutions, \$200 US for Individuals. For airmail add \$30, for receipt add \$10 US. Single copy prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.** No bank transfers.

Claims for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

European Journal of Gynaecological Oncology

www.irog.net

Instructions to Authors

SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storzione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószé, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publication cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three *manuscripts*, typed and double spaced should be submitted **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0**. Manuscripts without an electronic disk will not be accepted. **A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been published or submitted for publication elsewhere.** Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the *Corresponding Author*, responsible for revision and approval of the proofs, should be indicated. **Full-length articles should not exceed 8 printed pages including tables and references.**

After the *title page* (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: *Summary* (purpose of investigation, methods, results, conclusion - about 150 words), *Key words*, *Content* (a 20-word summary), *Introduction*, *Materials and Methods*, *Results*, *Discussion*, *Conclusion*, *Acknowledgement* (if any), *References*, *Tables*, *Legends*.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered approved**. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS

The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.** No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.

DISTINGUISHED EXPERT SERIES

- The potential and problems of screening for ovarian cancer** 241
 Y. Yokoyama, T. Higuchi, H. Mizunuma - *Hirosaki, JAPAN*
 The potential of ovarian cancer screening and the problems associated with it based on the reports published to date have been outlined and the results of our study are presented.

EDITORIAL ARTICLE

- Management of endometrial carcinoma with cervical involvement. An unsettled issue** 245
 J. Menczer - *Tel-Aviv, ISRAEL*
 Because of multiple confounding factors and conflicting data, the optimal management of endometrial carcinoma with cervical involvement remains to be established.

REVIEW ARTICLE

- Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature** 257
 F. Machado, J.R. Rodríguez, J.P.H. León, J.R. Rodríguez, J.J. Parrilla, L. Abad - *Murcia, SPAIN*
 Analysis of the literature on the need to screen patients using tamoxifen and the most appropriate diagnostic protocol are reported.

ORIGINAL ARTICLES

- Accuracy of ovarian cancer ICD-10 diagnosis in a Danish population-based hospital discharge registry** 266
 M.S. Tetsche, N. Nørgaard, M.V. Skriver, E.S. Andersen, T.L. Lash, H.T. Sørensen - *Boston, MA, USA*
 Hospital discharge data (ICD-10) can be a valuable tool for assessment of ovarian cancer outcome.
- Expression of cyclooxygenase-2 in endometrial adenocarcinoma** 271
 G. Kilic, B. Gurates, J. Garon, B. Arun, C.E. Lampley, R. Kurzel, R. Ashfaq - *Dallas, TX, USA*
 The role of COX-2 expression in endometrial adenocarcinoma is evaluated. The results were presented at the 33rd Annual Meeting of the Society of Gynecologic Oncology, March 19 2002, Miami, FL.
- Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas** 275
 B. Piura, A. Rabinovich - *Beer-Sheva, ISRAEL*
 Doxorubicin and ifosfamide demonstrated certain activity and high-grade hematological toxicity in five patients with advanced/recurrent uterine sarcomas.
- Color Doppler assessment of blood flow in endometrial cancer** 279
 W. Sawicki, B. Spiewankiewicz, J. Stelmachów, K. Cendrowski - *Warsaw, POLAND*
 The results of this research suggest that TVCD evaluation of endometrial cancer is a reliable method for assessing endometrial angiogenesis. The blood flow rates correspond to increased angiogenesis in endometrial cancers and might potentially be used as a good prediction factor for tumor progression and metastasis in affected women.
- Comparative evaluation of standard criteria and CA-125 in ovarian cancers treated with platinum or paclitaxel** 285
 G.C. Balbi, A. Cardone, M. Passaro, M. Battista, A. Monteverde, S. Visconti - *Naples, ITALY*
 Precise 50% or 75% CA-125 response criteria is as sensitive as standard criteria for assessing activity of therapy for ovarian cancers treated with platinum or paclitaxel.
- Endometrial stromal sarcoma - Observational evidence of a genetic background?** 288
 O. Reich, S. Regauer - *Graz, AUSTRIA*
 Patients with ESS may suffer from an inherited predisposition.
- The significance of Doppler flow in early detection of uterine sarcoma in older primigravida pregnancies** 291
 M. Gojnic, I. Likic, M. Pervulov, S. Petkovic, A. Fazlagic, B. Vasiljevic - *Belgrade, SERBIA AND MONTENEGRO*
 The significance of Doppler flow during pregnancy was analyzed. The aim of the study was to determine possibilities of timely diagnoses of malignant processes during pregnancy by using Doppler ultrasonography.

- Dynamics of cervical Langerhans cell counts in the course of HPV-positive CIN treatment with the use of human recombinant interferon gamma** 294
M. Sikorski, T. Bieda, M. Bobek, H. Żrubek - *Lublin, POLAND*
Interferon gamma significantly increases intraepithelial Langerhans cell counts in CIN which correlates with lesion regression *in vivo*.
- A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer** 299
S. Komiyama, H. Tsuji, S. Asai, J. Dokoh, M. Ishikawa, M. Mikami - *Saitama, JAPAN*
Weekly docetaxel therapy may be effective for recurrent mullerian carcinoma and maintains a good quality of life.
- Colposcopy vs Hybrid Capture II Assay in detection of cervical human papilloma virus infection** 303
C. Caruso, M. Le Donne, F. Antico, L. De Meo, R. La Spada, A. Arrigo, O. Triolo - *Messina, ITALY*
A significant association was found between a positive HC-II test for high-risk HPV types and high-grade transformation zone at colposcopy.
- Gestational trophoblastic disease in Sanliurfa, Southeast Anatolia, Turkey** 306
M. Harma, M. Harma, S. Yurtseven, N. Gungen - *Sanliurfa, TURKEY*
The previously reported extremely high rate of gestational trophoblastic disease in a center in Southeastern Anatolia was confirmed by a second center in the region.
- The significance of Doppler flow and anamnesis in the diagnosis of fallopian tube cancer** 309
M. Gojnic, M. Pervulov, S. Petkovic, G. Barisic, I. Stojanovic, T. Mostic, K. Jeremic - *Belgrade, SERBIA AND MONTENEGRO*
Uterine sarcoma can be pure or mixed. It is a very rare tumor appearing mostly in women in postmenopause and less than 50 cases have been described in the literature to date.
- Open surgical biopsy for nonpalpable breast lesions detected on screening mammography** 311
C. Markopoulos, E. Kouskos, K. Revenas, D. Mantas, Z. Antonopoulou, K. Kontzoglou, N. Nikiteas, V. Kyriakou - *Lesuas Island, GREECE*
Hook-wire localization of nonpalpable breast lesions, used successfully in our Breast Unit for many years, remains a simple, safe, and accurate method for diagnosis and treatment of early malignancies.
- Diagnostic value of the photodynamic method in the evaluation of lesions of the uterine cervix** 315
Z. Nowakowski, J. Stelmachów, B. Śpiewankiewicz, G. Gerulewicz, M.K. Chem - *Warsaw, POLAND*
The efficacy of photodynamic diagnosis (PDD) in evaluating lesions of the uterine cervix is reported and its place and efficiency among currently available diagnostic techniques are discussed.
- Extragenital cystic lesions of peritoneum, mesentery and retroperitoneum of the female. Clinicopathological characteristics of 19 cases** 323
A. Kondi-Pafiti, E. Kairi-Vassilatou, H. Spanidou-Carvouni, K. Kontogianni-Katsarou, G. Anastassopoulos, K. Papadias, V. Smyrniotis - *Athens, GREECE*
Clinical and immunopathological characteristics of 19 cases of extragenital cystic/peritoneal lesions are presented.
- CASE REPORTS**
- Tumors of low malignant potential arising in the fallopian tube: Case reports** 327
J.A. Villella, S.A. Pauli, J. Wang, M. Intengan, S. Lele - *New York, NY (USA)*
Serous tumors of low malignant potential of the fallopian tube are rare entities, with few published reports on the management.
- Bilateral gonadoblastoma with extended calcification: Case report of a tumor developing on dysgenetic gonads** 330
A. Kondi-Pafiti, D. Grapsa, D. Hasiakos, A. Kontorabdis - *Athens, GREECE*
A case of bilateral gonadoblastoma arising in dysgenetic gonads is presented and the difficulties in the histological diagnosis of this rare tumor are discussed.
- Primary leiomyosarcoma of the fallopian tube: A case report** 333
L. Mariani, M. Quattrini, M. Galati, B. Dionisi, G. Piperno, F. Modafferi, C. Sbiroli - *Rome, ITALY*
A rare case of primary leiomyosarcoma arising from the left fallopian tube in a perimenopausal 48-year-old woman is presented. Treatment and results are reported with a review of the international literature.
- Bilateral metastatic breast cancer as the first manifestation of ovarian cancer: Case report** 336
H. Gökaslan, P. Yörük, T. Pekin, Z. Kavak, F. Eren - *Istanbul, TURKEY*
A case of a patient with bilateral metastatic breast cancer as the first manifestation of ovarian cancer is presented.

- Palmar fasciitis and polyarthritis associated with secondary ovarian carcinoma. Case report** 339
 Ch. K. Giannakopoulos, G.K. Kyriakidou, G.E. Toufexi - *Athens, GREECE*
 A rare case of palmar fasciitis and polyarthritis paraneoplastic syndrome associated with ovarian and pancreatic carcinoma is presented.
- Mixed serous and endometrioid carcinoma of the fallopian tube: A case report with literature review** 342
 M.F. Acikalin, S. Ozalp, O.T. Yalcin, B. Peker - *Eskisehir, TURKEY*
 A case of mixed serous and endometrioid carcinoma of the fallopian tube is presented and the related literature is reviewed.
- Image findings of a tailgut cyst. Case report and short review of the literature** 345
 V.T. Skiadas, V. Koutoulidis, H. Primetis, Ch. Ladopoulos, L.A. Mouloupoulos, A. Gouliamos, L. Vlahos - *Athens, GREECE*
 The image findings of a tailgut cyst in all modalities are presented together with a short review of the literature.

ERRATA - CORRIGE

FNAC: Its role, limitations and perspective in the preoperative diagnosis of breast cancer - P. Zagorianakou¹, S. Fiaccavento², N. Zagorianakou¹, G. Makrydimas³, N.J. Agnantis¹ - *Ioannina, Greece*
 Department of ¹Pathology, Medical School, University of Ioannina, ²Department of Pathology, Casa di Cura Poliambulanza, Brescia (Italy); ³Department of Obstetrics and Gynaecology, Medical School, University of Ioannina (Greece)
 Vol. XXVI, n. 2, 2005, pag. 143

Errata: P. Zagorianakou¹, S. Fiaccavento², N. Zagorianakou¹, G. Makrydimas³, N.J. Agnantis¹

Corrige: P. Zagorianakou¹, S. Fiaccavento², N. Zagorianakou¹, G. Makrydimas³, D. Stefanou¹, N.J. Agnantis¹

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY

Vol. XXVI, Number 3, 2005

ISSN: 0392-2936

I.R.O.G. CANADA, Inc.

Publisher office: 4900 Côte St. Luc - Apt. 212 - Montréal, Québec H3W 2H3 (Canada) - Tél.: (514) 4893640-4893242 - Fax: (514) 4854513

E-mail: canlux@mgroun-online.com - www.irog.net

ALL RIGHTS RESERVED

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopies, recordings, nor any information storage and retrieval system without written permission from the copyright owner.

Printed in Italy